Our Bureau

Mumbai, Dec. 29

ETHYPHARM said it plans to invest $3 million in its plant and R&D facility in India.

The company will be investing $2 million to upgrade its existing WHO GMP approved production facility at Ambernath, near Mumbai, to EUGMP standards.

Another $1 million will be invested in upgrading the R&D centre, also located at Ambernath.

Ethypharm specialises in novel drug delivery systems (NDDS). Globally the market for NDDS is about $75 billion.

India represents a huge opportunity both as a market as well as a manufacturing clinical and R&D hub.

"By licensing out our NDDS technologies to Indian companies we hope to have a significant impact in the cost of medicine in the country as well as on patient compliance," the company said in a news release.

(This article was published in the Business Line print edition dated December 30, 2005)
XThese are links to The Hindu Business Line suggested by Outbrain, which may or may not be relevant to the other content on this page. You can read Outbrain's privacy and cookie policy here.